AU783933B2 - Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers - Google Patents
Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers Download PDFInfo
- Publication number
- AU783933B2 AU783933B2 AU39190/01A AU3919001A AU783933B2 AU 783933 B2 AU783933 B2 AU 783933B2 AU 39190/01 A AU39190/01 A AU 39190/01A AU 3919001 A AU3919001 A AU 3919001A AU 783933 B2 AU783933 B2 AU 783933B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- thiazolidine
- dicarboxylic acid
- tolerable salts
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- JCAKCGQZNBEITC-UHFFFAOYSA-N 2-methyl-1,3-thiazolidine-2,4-dicarboxylic acid Chemical compound OC(=O)C1(C)NC(C(O)=O)CS1 JCAKCGQZNBEITC-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 150000003839 salts Chemical class 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000000824 cytostatic agent Substances 0.000 claims description 9
- 230000001085 cytostatic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 206010044285 tracheal cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 14
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 91
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 46
- 229960003180 glutathione Drugs 0.000 description 45
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 40
- 229960004308 acetylcysteine Drugs 0.000 description 40
- 108010024636 Glutathione Proteins 0.000 description 26
- 239000004201 L-cysteine Substances 0.000 description 23
- 235000013878 L-cysteine Nutrition 0.000 description 23
- 239000000126 substance Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229940076788 pyruvate Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 150000003548 thiazolidines Chemical class 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10008159 | 2000-02-15 | ||
| DE10008159A DE10008159B4 (de) | 2000-02-15 | 2000-02-15 | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
| PCT/DE2001/000656 WO2001060343A2 (de) | 2000-02-15 | 2001-02-15 | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3919001A AU3919001A (en) | 2001-08-27 |
| AU783933B2 true AU783933B2 (en) | 2005-12-22 |
Family
ID=7631906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU39190/01A Ceased AU783933B2 (en) | 2000-02-15 | 2001-02-15 | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6943185B2 (enExample) |
| EP (1) | EP1255538B1 (enExample) |
| JP (1) | JP2003522782A (enExample) |
| CN (1) | CN1400899A (enExample) |
| AT (1) | ATE252383T1 (enExample) |
| AU (1) | AU783933B2 (enExample) |
| CA (1) | CA2399709C (enExample) |
| DE (2) | DE10008159B4 (enExample) |
| EA (1) | EA004592B1 (enExample) |
| ES (1) | ES2208571T3 (enExample) |
| MX (1) | MXPA02007903A (enExample) |
| PL (1) | PL357179A1 (enExample) |
| PT (1) | PT1255538E (enExample) |
| TR (1) | TR200302134T4 (enExample) |
| WO (1) | WO2001060343A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050197406A1 (en) * | 1999-04-14 | 2005-09-08 | Li Chiang J. | Method of treatment of lung cancer |
| DE10008159B4 (de) * | 2000-02-15 | 2005-08-18 | Rudy Dr. Susilo | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
| CN101838218A (zh) * | 2002-02-28 | 2010-09-22 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
| WO2005021486A1 (ja) * | 2003-08-29 | 2005-03-10 | Japan Tobacco Inc. | エステル誘導体及びその医薬用途 |
| DE102004021658A1 (de) * | 2004-05-03 | 2005-12-01 | Rudy Dr. Susilo | Kombinationspräparate enthaltend 2-Methylthiazolidin-2,4-dicarbonsäure |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
| JP5439849B2 (ja) * | 2008-02-28 | 2014-03-12 | 味の素株式会社 | システイン誘導体 |
| JP5378713B2 (ja) * | 2008-06-19 | 2013-12-25 | 日本理化学薬品株式会社 | 外用組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19711053C2 (de) * | 1997-03-03 | 1999-09-02 | Rommelspacher | Kombinationspräparat aus 2-Methyl-thiazolidin-2,4-dicarbonsäure und Paracetamol |
| DE19711052C2 (de) * | 1997-03-03 | 1999-09-23 | Hans Rommelspacher | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure als Mukolytikum |
| DE10008159B4 (de) * | 2000-02-15 | 2005-08-18 | Rudy Dr. Susilo | Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure und/oder ihrer physiologisch verträglichen Salze als Antikrebsmittel |
-
2000
- 2000-02-15 DE DE10008159A patent/DE10008159B4/de not_active Expired - Fee Related
-
2001
- 2001-02-15 US US10/182,442 patent/US6943185B2/en not_active Expired - Fee Related
- 2001-02-15 CN CN01805095A patent/CN1400899A/zh active Pending
- 2001-02-15 ES ES01913699T patent/ES2208571T3/es not_active Expired - Lifetime
- 2001-02-15 TR TR2003/02134T patent/TR200302134T4/xx unknown
- 2001-02-15 AT AT01913699T patent/ATE252383T1/de not_active IP Right Cessation
- 2001-02-15 PT PT01913699T patent/PT1255538E/pt unknown
- 2001-02-15 PL PL01357179A patent/PL357179A1/xx not_active Application Discontinuation
- 2001-02-15 EP EP01913699A patent/EP1255538B1/de not_active Expired - Lifetime
- 2001-02-15 AU AU39190/01A patent/AU783933B2/en not_active Ceased
- 2001-02-15 EA EA200200853A patent/EA004592B1/ru not_active IP Right Cessation
- 2001-02-15 WO PCT/DE2001/000656 patent/WO2001060343A2/de not_active Ceased
- 2001-02-15 CA CA002399709A patent/CA2399709C/en not_active Expired - Fee Related
- 2001-02-15 MX MXPA02007903A patent/MXPA02007903A/es active IP Right Grant
- 2001-02-15 DE DE50100833T patent/DE50100833D1/de not_active Expired - Lifetime
- 2001-02-15 JP JP2001559441A patent/JP2003522782A/ja active Pending
-
2005
- 2005-04-29 US US11/117,569 patent/US20050187271A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| NEOPLASMA 43(4):259-263, WLODEK B ET AL, 1996 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE252383T1 (de) | 2003-11-15 |
| EP1255538A2 (de) | 2002-11-13 |
| PT1255538E (pt) | 2004-03-31 |
| EA004592B1 (ru) | 2004-06-24 |
| DE50100833D1 (de) | 2003-11-27 |
| DE10008159A1 (de) | 2001-09-06 |
| MXPA02007903A (es) | 2004-09-10 |
| EA200200853A1 (ru) | 2003-02-27 |
| DE10008159B4 (de) | 2005-08-18 |
| US20050187271A1 (en) | 2005-08-25 |
| EP1255538B1 (de) | 2003-10-22 |
| CN1400899A (zh) | 2003-03-05 |
| PL357179A1 (en) | 2004-07-26 |
| WO2001060343A3 (de) | 2002-05-30 |
| TR200302134T4 (tr) | 2004-01-21 |
| ES2208571T3 (es) | 2004-06-16 |
| WO2001060343A2 (de) | 2001-08-23 |
| AU3919001A (en) | 2001-08-27 |
| US6943185B2 (en) | 2005-09-13 |
| US20030149085A1 (en) | 2003-08-07 |
| JP2003522782A (ja) | 2003-07-29 |
| CA2399709A1 (en) | 2001-08-23 |
| CA2399709C (en) | 2007-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7009053B2 (ja) | 有機セレン化合物の組成物およびその使用方法 | |
| US20240366719A1 (en) | Tissue catalyzed growth of polymer as epithelial linings for therapy | |
| US7820640B2 (en) | Methods for treating hearing loss | |
| EP2023911B1 (de) | Verbindungen a-r-x zur herstellung von pharmazeutischen zubereitungen | |
| AU783933B2 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-MTDC) and/or physiologically compatible salts for treating and/or preventing cancers | |
| WO2009052116A1 (en) | Methods for treating a variety of diseases and conditions, and compounds useful therefor | |
| KR100949318B1 (ko) | 화학요법의 바람직하지 않은 작용을 개선하기 위한 방법과조성물 | |
| JP2004502743A (ja) | 薬学的化合物の還元体の製造、安定化および使用 | |
| US20190307726A1 (en) | Pharmaceutical formulations | |
| AU2007204757B2 (en) | Lanthionine-related compounds for the treatment of inflammatory diseases | |
| KR20170066432A (ko) | 정신병적 장애를 치료하기 위한 방법 및 조성물 | |
| Lahiani et al. | Novel synthetic PEGylated conjugate of α-lipoic acid and tempol reduces cell death in a neuronal PC12 clonal line subjected to ischemia | |
| US9102636B2 (en) | Analgesic compounds, compositions, and uses thereof | |
| TW202421107A (zh) | 難治性癌症之預防或治療用之醫藥組合物 | |
| EP4125997A1 (en) | New method to treat the hepatotoxicity induced by amanitins | |
| Waniewski et al. | Intrahippocampal kainic acid reduces glutamine synthetase | |
| RU2813928C1 (ru) | Антиоксидантный препарат для лечения и профилактики неврологических патологий у животных | |
| JP4734560B2 (ja) | キノン体若しくはキノン体前駆体の毒性に起因する障害に対する予防治療剤 | |
| WO2020262317A1 (ja) | 認知症の治療及び予防薬 | |
| US20090298782A1 (en) | Compounds for Delivering Amino Acids or Peptides with Antioxidant Activity into Mitochondria and Use Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |